Dec 22, 2022 | Teresa Miceli
Attending the 64th American Society of Hematology (ASH) Annual Meeting, I am continually reminded of how far we have come in the treatment landscape of multiple myeloma (MM) since I became a nurse I 1991. Acronyms of drug regimens that, for the most part, are no...
Dec 12, 2022 | Jack Aiello
Today’s oral presentations examined prognostic factors for newly diagnosed multiple myeloma patients, new drugs, and optimized treatment approaches, as well as prognostic markers. I’ll show some of the abstract results below from those sessions. We also met with...
